Case Report of First-line Chemotherapy of an Advanced Lung Cancer Patient Using Bevacizumab Combined With Pemetrexed Disodium and Carboplatin

A single case of a male stage-IV lung cancer patient is reported, there were exon 19 deletion mutations in the epidermal growth factor receptor (EGFR). Intra-, and extrapulmonary, lesions occurred a month after gefitinib and erlotinib applications. Patient was then switched to the first-line chemotherapy program. Both types of lesions significantly improved four weeks after a combined therapy of pemetrexed disodium + carboplatin+ bevacizumab (7.5mg/Kg d1), two weeks after continuous therapy with pemetrexed disodium + bevacizumab (7.5mg/ Kg d1). Short-term efficacy was assessed as PR, without significant adverse effects, reflecting program efficacy and good tolerance.